Zymeworks and BeiGene Announce License and Collaboration Agreement for Zymeworks' HER2-Targeted Therapeutic Candidates, ZW25 and ZW49, in Asia-Pacific and Research and License Agreement for Zymeworks' Azymetric(TM) and EFECT(TM) Platforms Globally

Stock Information for Zymeworks Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Zymeworks Inc.

Zymeworks Announces Positive Topline Data in the Pivotal HERIZON-BTC-01 Trial of Zanidatamab
Zanidatamab Clinical Data Selected For Presentation At The American Society Of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium
Zymeworks Early R&D Day Highlights Progress in Development of Novel Pipeline Assets and Applications of Proprietary Next-Generation Technology Platforms
Zymeworks To Host Conference Call on Exclusive Licensing Agreement of Zanidatamab
Jazz Pharmaceuticals and Zymeworks Announce Exclusive License Agreement to Develop and Commercialize Zanidatamab, a HER2-Targeted Bispecific Antibody
Zymeworks to Host Third Quarter Results Conference Call
Zymeworks Completes Plan to Become Delaware Corporation
Zymeworks Announces Results of Special Meeting

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.